Valuation: Lundbeck

Market Cap 41.34B 6.45B 5.53B 5.19B 4.74B 8.94B 615B 8.98B 61.29B 23.82B 311B 24.21B 23.68B 1,026B P/E 2026 *
9.2x
P/E 2027 * 9.03x
Enterprise Value 45.35B 7.07B 6.06B 5.69B 5.2B 9.8B 675B 9.85B 67.23B 26.12B 341B 26.55B 25.97B 1,126B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.58x
Free-Float
30.74%
Yield 2026 *
3.71%
Yield 2027 * 3.34%
1 day-2.13%
1 week+12.21%
Current month+14.86%
1 month+14.70%
3 months+15.83%
6 months+18.48%
Current year+14.23%
1 week 40.1
Extreme 40.1
42.6
1 month 35.1
Extreme 35.1
42.6
Current year 31.4
Extreme 31.4
42.6
1 year 31.4
Extreme 31.4
42.6
3 years 23.3
Extreme 23.3
42.6
5 years 21.94
Extreme 21.935
42.6
10 years 21.94
Extreme 21.935
42.6
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 66 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-2.13%+12.21% - - 6.59B
-0.93%+3.15%+32.07%+111.82% 106B
+0.20%+1.46%+63.24%+172.05% 55.33B
-0.70%-2.07%+0.71%+261.78% 23.53B
+1.11%-0.37%-15.97%-12.04% 8.13B
+0.48%-5.74%-40.91%-26.27% 7.12B
+1.07%-4.67%-19.04%-26.22% 6.35B
-2.06%-4.78%+7.07%+21.44% 6.59B
-1.26%+1.67%-2.60%+19.10% 5.17B
+0.93%+7.24%+240.52%+385.04% 3.84B
Average -0.33%+0.48%+29.46%+100.75% 24.62B
Weighted average by Cap. -0.50%+0.84%+33.01%+129.73%

Financials

2026 *2027 *
Net sales 25.92B 4.04B 3.46B 3.25B 2.97B 5.6B 386B 5.63B 38.42B 14.93B 195B 15.17B 14.84B 643B 26.05B 4.06B 3.48B 3.27B 2.99B 5.63B 388B 5.66B 38.63B 15.01B 196B 15.25B 14.92B 647B
Net income 4.59B 715M 613M 575M 526M 992M 68.23B 996M 6.8B 2.64B 34.45B 2.69B 2.63B 114B 4.65B 725M 621M 583M 533M 1.01B 69.16B 1.01B 6.89B 2.68B 34.92B 2.72B 2.66B 115B
Net Debt 4B 624M 535M 502M 459M 866M 59.55B 869M 5.93B 2.31B 30.07B 2.34B 2.29B 99.36B -178M -27.71M -23.75M -22.3M -20.38M -38.43M -2.64B -38.6M -263M -102M -1.33B -104M -102M -4.41B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
26-08-26 DKK 41.35 -2.13% 80,250
26-08-25 DKK 42.25 +3.05% 227,799
26-08-24 DKK 41.00 +1.23% 127,581
26-08-21 DKK 40.50 +0.50% 120,723
26-08-20 DKK 40.30 -3.93% 261,361
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
41.80DKK
Average target price
48.73DKK
Spread / Average Target
+16.58%

Quarterly revenue - Rate of surprise